
SYNTAX Left Main Classification & Outcomes

Keith Dawkins MD FRCP FACC FSCAI Associate Chief Medical Officer Senior Vice President Boston Scientific Corporation

Stitution it TCT Asia Pacific 2009 April 22-24, 2009 The Convention Center of Sheraton Grande Walkerhill Hotel. Seoul. Korea





Conflicts of Interest

- Employee
 - Boston Scientific Corporation
- Stockholder
 - Boston Scientific Corporation

BNJ

334,593–644 No 7594 Clinical research ISSN 0959-8138 24 March 2007 | bmj.com

STENTING OR SURGERY?

PLUS Your views on MTAS Tests in postmenopausal bleeding Organophosphorus poisoning The Change Page

March 24th, 2007

Current controversies Surgery is the best intervention for severe coronary artery disease

David P Taggart

A multidisciplinary approach is essential, but best evidence favours surgery over percutaneous intervention

artery bypass grafting. The current tendency of some cardiologists to exclusively investigate and treat patients with severe multivessel disease without a surgical opinion not only belittles the traditional multidisciplinary approach but ensures that the best and most balanced advice is unlikely to be consistently offered. Most importantly, by effectively denying patients the opportunity of making a fully informed choice, it falls far short of best practice.


Why is Left Main Stem PCI Different?

Anatomic Variations

- Short vs. Long LMS
- Ostial, Shaft, Distal lesions
- Protected vs. Unprotected

Alternative Strategies to PCI

- Medical Treatment
- Surgical Revascularisation
- Co-Morbidity
 - LV Function
 - Emergency presentation
 - Diabetes Mellitus
- PCI: Additional Technology
 - Intravascular Ultrasound
 - Debulking (Directional & Rotational Atherectomy)
 - Bifurcation Techniques
- Concern relating to late outcomes
- Difficulties assessing the literature






LMS PCI








Stent Thrombosis

LMS: Medical Treatment



Left Main Stem




Medical Treatment

Mortality (5 years) = 36.5% Odds Ratio (*vs.* CABG) = 0.32 [0.15-0.70], p=0.04

Lancet 1994;344:563-570


Contemporary Trials of LM CABG vs. PCI Superior Treatment Modality for Outcomes



Trial [*]	N	$Death^{\dagger}$	MI	Stroke	Revasc
Wu 2008 (DES)	112	ND	n/a	n/a	CABG Better
MAIN-COMPARE 2008	1102		ND		
LEMANS 2008	105				
Palmerini 2006	311				
Sanmartin 2007	341			ND	
Chieffo 2006	249		PCI Better	PCI Better	
Lee 2006	173		ND		ND
Makikallio 2008	287			ND	
Rodés-Cabau 2008 ⁺	249			n/a	n/a
Brener 2008	287		n/a		
White 2008	343				


*Studies with >100 patients per arm reported; +Cardiac death ND=no difference; n/a=not available/not reported

Comparison of Surgical & Medical Survival in Patients with Left Main Disease (Normal LV)




Circ 1995;91:2325-2334

CABG for Left Main Disease Duke Database



CABG for Left Main Disease NYS Database



Left Main PCI?



...CABG using IMA grafting is the 'gold standard' for treatment of unprotected left main disease and has proven benefit on long-term outcomes. The use of DES has shown encouraging short-term outcomes, but long-term follow-up is needed...

It is likely that during the progress of their disease, many patients will benefit from a combined application of percutaneous and surgical techniques, taking advantage of the low morbidity of percutaneous methods and the established long-term benefit of surgical revascularization with arterial conduits.

J Am Coll Cardiol 2006;47:e1-e121

Appropriate Revascularization?

ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization

A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology

Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography

Coronary revascularization is appropriate when the expected benefits, in terms of survival or health outcomes (symptoms, functional status, and/or quality of life) exceed the expected negative consequences of the procedure.

J Am Coll Cardiol 2009;53:530-553

Increasing Numbers of Studies Exploring PCI as a Treatment Option in LM Disease...

Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation fo Unprotected Left Main Coronary Artery

One-year clinical outcomes of protected and unprotected left main coronary artery stenting

Unprotected Left Main Coronary Artery The DELFT (Drug Eluting stent for LeFT main) R Vidya S. Banka^a, Howard C. Herrmann^a, John W. Hirshfeld Jr^a, Stephen E. Kimmel^a, Daniel M. Kolansky^a, Phillip A. Horwitz^a,

Emanuele Meliga MD *+ Hector Manuel Garcia-Garcia MD MS François Schiele^b Jean-Pierre I Rassand^b Robert I Wilensky^a*

Alaide Chieffo, N Stephen Cook, N Igor F. Palacios, Ron van Dombu Comparison of Drug-Eluting Stents Versus Surgery for Unprotected Left Main Coronary Artery Disease

Origi

Marcelo Sanmartín, PhD^{a,*}, José Antonio Baz, MD^a, Ramon Claro, MD^a, Vanesa Asorey, MD^b, Darío Durán, PhD^b, Gonzalo Pradas, MD^b, and Andrés Iñiguez, PhD^a

Long-term outcomes following drug-eluting stent implantation in unprotected left main bifurcation lesions

Comparison of Coronar Stents versus Coronary-Artery Bypass Grafting for Left Main Percutaneous Coronary Ii Coronary Artery Disease

Stents for Unprotected Le Michael S. Lee, MD, Nikhil Kapoor, MI James Forrester, MD, Saibal Kar, MD, S Alfredo Trento, MD, Prediman K. Shah,

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

MARCH 5, 2009

VOL. 360 NO. 10

SYNTA

Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease

Patrick W. Serruys, M.D., Ph.D., Marie-Claude Morice, M.D., A. Pieter Kappetein, M.D., Ph.D., Antonio Colombo, M.D., David R. Holmes, M.D., Michael J. Mack, M.D., Elisabeth Ståhle, M.D., Ted E. Feldman, M.D., Marcel van den Brand, M.D., Eric J. Bass, B.A., Nic Van Dyck, R.N., Katrin Leadley, M.D., Keith D. Dawkins, M.D., and Friedrich W. Mohr, M.D., Ph.D., for the SYNTAX Investigators*

N Engl J Med 2009;360:961-972

SYNTAX Background



SYNTAX was designed to answer the following three questions in patients with left main and/or 3VD:


- How does modern CABG compare to PCI in highrisk patients eligible for both techniques?
- Which patient group continues to be solely eligible for CABG?
- What characterizes complex patients not eligible for CABG?

Patient Profiling

Local Heart team (surgeon & interventional cardiologist) assessed each patient in regards to :

- Patient's operative risk (EuroSCORE & Parsonnet score)
- Coronary lesion complexity (Newly developed SYNTAX score)
- Goal: SYNTAX score to provide guidance on optimal revascularization strategies for patients with high risk lesions

Sianos et al, EuroIntervention 2005;1:219-227 Valgimigli et al, Am J Cardiol 2007;99:1072-1081 Serruys et al, EuroIntervention 2007;3:450-459



Calcification

Thrombus

Leaman score, Circ 1981;63:285-299 Lesions classification ACC/AHA, Circ 2001;103:3019-3041 Bifurcation classification, CCI 2000;49:274-283 CTO classification, J Am Coll Cardiol 1997;30:649-656

syntaX)

Left

Main

No. &

of lesion

Dominance Location


SYNTAX


SCORE


SYNTAX Statistical Analysis





Non-inferiority was not met for the primary endpoint (MACCE at 12 months), further comparisons for the LM and 3VD subgroups are observational only and hypothesis generating




























Stratified by Baseline SYNTAX Score LM Subset



Revascularization at 12 Months Stratified by Baseline SYNTAX Score *LM Subset*



SYNTAX

SYNTAX Facts (One Year)

Overall, number of CABG needed to avoid one re-PCI = 13, at the cost of almost 4x as many strokes

syntaX

- In the Left Main subset, number of CABG needed to avoid one re-PCI = 19, at the cost of 9x as many strokes
- In the Left Main + 3VD subset, number of CABG needed to avoid one re-PCI = 11



Percutaneous Coronary Intervention With Stent Implantation Versus Coronary Artery Bypass Surgery for Treatment of Left Main Coronary Artery Disease Is It Time to Change Guidelines?

Seung-Jung Park, MD, PhD; Duk-Woo Park, MD, PhD

Abstract—On the basis of clinical trials comparing coronary-artery bypass grafting (CABG) with medical therapy, current guideline recommend CABG as the treatment of choice for patients with asymptomatic ischemia, stable angina, or unstable angina/non-ST elevation myocardial infarction who have left main coronary artery disease. Percutaneous coronary intervention can be selectively performed in patients who are candidates for revascularization but who are ineligible for CABG. However, because of advances in periprocedural and postprocedural medical care in patients undergoing either CABG or percutaneous coronary intervention with stenting, new evaluation, and a review of current indications, may be required to determine the standard of care for patients with left main coronary artery disease. Current evidences indicate that stenting results in mortality and morbidity rates that compared favorably with those seen after CABG, suggesting that a current guideline (the Class III recommendation of percutaneous coronary intervention for unprotected left main coronary artery disease) may no longer be justified. Data from several extensive registries and a large clinical trial may have prompted many interventional cardiologists to select percutaneous coronary intervention with stenting as an alternative revascularization strategy for such patients. In addition, these data may inform future guidelines and support the need for well-designed, adequately powered, prospective, randomized trials comparing the 2 revascularization strategies. The cumulative evidence from ongoing and future clinical trials will change the current clinical practice of revascularization for unprotected left main coronary artery disease, which was introduced several decades ago and which has continued to date without major revision. (Circ Cardiovasc Intervent. 2009;2:59-68.)

Conclusions:

- The SYNTAX trial provides a unique prespecified Left Main dataset (n=705)
- There are no significant safety differences (Death, CVA, AMI) between PCI (TAXUS Express) and CABG at one year
- In lower complexity Left Main disease, PCI treatment is favorable
- The positive Left Main PCI results are both hypothesis generating and thought provoking, but fit with the available literature and clinical experience